E-LIB Suche - Ergebnisse für: Atagi, Shinji

1

Treatment patterns and clinical outcomes of resectable clin..:

Tsuboi, Masahiro ; Murakami, Haruyasu ; Harada, Hideyuki...
Thoracic Cancer. 15 (2024) 20 - p. 1541-1552 , 2024

Link: https://doi.org/10.1111/..

2

Long‐term experience with tepotinib in Japanese patients wi..:

Morise, Masahiro ; Kato, Terufumi ; Matsumoto, Shingo...
Cancer Science. 115 (2024) 4 - p. 1296-1305 , 2024

Link: https://doi.org/10.1111/..

3

Standard versus low‐dose nab‐paclitaxel in previously treat..:

Takeuchi, Susumu ; Kubota, Kaoru ; Sugawara, Shunichi...
Cancer Medicine. 12 (2023) 8 - p. 9133-9143 , 2023

Link: https://doi.org/10.1002/..

4

Survival Impact of Second-Line Immune Checkpoint Inhibitors..:

Kogure, Yoshihito ; Kada, Akiko ; Hashimoto, Hiroya...
JTO Clinical and Research Reports. 4 (2023) 6 - p. 100514 , 2023

Link: https://doi.org/10.1016/..

5

A randomized phase III study of docetaxel alone versus doce..:

Atagi, Shinji ; Daimon, Takashi ; Okishio, Kyoichi...
Thoracic Cancer. 14 (2023) 29 - p. 2941-2949 , 2023

Link: https://doi.org/10.1111/..

6

Clinical benefit of platinum doublet combination therapy in..:

Shimokawa, Mototsugu ; Kanazu, Masaki ; Saito, Ryusei...
Thoracic Cancer. 14 (2023) 17 - p. 1597-1605 , 2023

Link: https://doi.org/10.1111/..

7

Neoadjuvant nivolumab plus chemotherapy in resectable non‐s..:

Mitsudomi, Tetsuya ; Ito, Hiroyuki ; Okada, Morihito...
Cancer Science. 115 (2023) 2 - p. 540-554 , 2023

Link: https://doi.org/10.1111/..

8

Standard versus low‐dose nab‐paclitaxel in previously treat..:

Susumu Takeuchi ; Kaoru Kubota ; Shunichi Sugawara...
https://doi.org/10.1002/cam4.5652. , 2023

Link: https://doi.org/10.1002/..

9

Survival Impact of Second-Line Immune Checkpoint Inhibitors..:

Yoshihito Kogure, MD, PhD ; Akiko Kada, MPH ; Hiroya Hashimoto, PhD...
http://www.sciencedirect.com/science/article/pii/S266636432300053X. , 2023

Link: https://doi.org/10.1016/..

10

Clinical benefit of platinum doublet combination therapy in..:

Shimokawa, Mototsugu ; Kanazu, Masaki ; Saito, Ryusei...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260489/. , 2023

Link: http://www.ncbi.nlm.nih...

11

A randomized phase III study of docetaxel alone versus doce..:

Shinji Atagi ; Takashi Daimon ; Kyoichi Okishio...
https://doi.org/10.1111/1759-7714.15080. , 2023

Link: https://doi.org/10.1111/..

12

A randomized phase III study of docetaxel alone versus doce..:

Atagi, Shinji ; Daimon, Takashi ; Okishio, Kyoichi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569902/. , 2023

Link: http://www.ncbi.nlm.nih...

13

Standard versus low‐dose nab‐paclitaxel in previously treat..:

Takeuchi, Susumu ; Kubota, Kaoru ; Sugawara, Shunichi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166935/. , 2023

Link: http://www.ncbi.nlm.nih...

14

Clinical benefit of platinum doublet combination therapy in..:

Mototsugu Shimokawa ; Masaki Kanazu ; Ryusei Saito...
https://doi.org/10.1111/1759-7714.14904. , 2023

Link: https://doi.org/10.1111/..

15

Predicting systemic therapy toxicity in older adult patient..:

Kanazu, Masaki ; Shimokawa, Mototsugu ; Saito, Ryusei...
Journal of Geriatric Oncology. 13 (2022) 8 - p. 1216-1222 , 2022

Link: https://doi.org/10.1016/..